Detecting Microsatellite Instability in Endometrial, Colon, and Stomach Cancers Using Targeted NGS.
endometrial cancers
microsatellite instability
targeted NGS
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
12
07
2023
revised:
19
09
2023
accepted:
19
09
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
To develop a method for testing the MSI based on targeted NGS. Based on the results of previous studies, 81 microsatellite loci with high variability in MSI-H tumors were selected, and a method for calculating the MSI score was developed. Using the MSI score, we defined the MSI status in endometral (162), colon (153), and stomach (190) cancers. Accuracy of the MSI scores was evaluated by comparison with MMR immunohistochemistry for 137 endometrium (63 dMMR and 74 pMMR), 76 colon (29 dMMR and 47 pMMR), and 81 stomach (8 dMMR and 73 pMMR) cancers. Classification of MSS and MSI-H tumors was performed with AUC (0.99), sensitivity (92%), and specificity (98%) for all tumors without division into types. The accuracy of MSI testing in endometrial cancer was lower than for stomach and colon cancer (0.98, 87%, and 100%, respectively). The use of 27 loci only, the most informative for endometrial cancer, increased the overall accuracy (1.00, 99%, and 99%). Comparison of MSI score values in 505 tumors showed that MSI score is significantly higher in colon ( The MSI score accurately determines MSI status for endometrial, colon, and stomach cancers and can be used to quantify the degree of MSI.
Identifiants
pubmed: 37894432
pii: cancers15205065
doi: 10.3390/cancers15205065
pmc: PMC10605658
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Russian state-funded project for ICBFM SB RAS
ID : 121031300045-2
Références
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Clin Cancer Res. 2019 Dec 1;25(23):7035-7045
pubmed: 31383735
Clin Chim Acta. 2020 Mar;502:207-213
pubmed: 31730810
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
J Mol Diagn. 2018 Mar;20(2):225-231
pubmed: 29277635
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178
J Comput Biol. 2017 Nov;24(11):1138-1143
pubmed: 28715235
Cancer Prev Res (Phila). 2017 Feb;10(2):108-115
pubmed: 27965287
PLoS One. 2013 Nov 07;8(11):e79737
pubmed: 24244552
Oncol Lett. 2020 Aug;20(2):1982-1988
pubmed: 32724444
Clin Chem. 2018 Jun;64(6):950-958
pubmed: 29632127
Nat Commun. 2017 Jun 06;8:15180
pubmed: 28585546
PLoS Comput Biol. 2020 Dec 30;16(12):e1008468
pubmed: 33378360
PLoS One. 2018 Aug 29;13(8):e0203052
pubmed: 30157243
Arch Pathol Lab Med. 2022 Oct 1;146(10):1194-1210
pubmed: 35920830
Front Oncol. 2018 Dec 12;8:621
pubmed: 30631754
Science. 2019 May 3;364(6439):485-491
pubmed: 31048490
BMC Cancer. 2018 Dec 4;18(1):1218
pubmed: 30514259
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
JCO Precis Oncol. 2017;2017:
pubmed: 30211344
Chin Med J (Engl). 2023 May 5;136(9):1082-1088
pubmed: 37022939
Gastroenterology. 2010 Jun;138(6):2073-2087.e3
pubmed: 20420947
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
Mod Pathol. 2013 Jan;26(1):131-8
pubmed: 22918162
Ann Surg Oncol. 2012 Mar;19(3):809-16
pubmed: 21879275
Cell. 2013 Nov 7;155(4):858-68
pubmed: 24209623
Sci Rep. 2021 Jun 18;11(1):12880
pubmed: 34145315
J Mol Diagn. 2015 Nov;17(6):705-14
pubmed: 26322950
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933